• Earlier this week, Biogen drew attention as Axtria honored its transformation leaders at Axtria Ignite 2026, while the company also advanced its push beyond declining multiple sclerosis and Spinraza sales with newer drugs such as Leqembi, Skyclarys, Qalsody, and Zurzuvae.
• More recently, Biogen’s agreement to acquire RayThera Inc. for US$1.00 billion and the FDA’s Breakthrough Therapy designation for Salanersen have highlighted management’s effort to refresh the pipeline just as competition and pricing pressure intensify on its established products.
• We’ll now examine how Biogen’s US$1.00 billion RayThera acquisition could influence the company’s existing investment narrative and long-term growth assumptions.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

Biogen Investment Narrative Recap

To own Biogen today, you need to believe that newer neurology launches and a refreshed pipeline can eventually shoulder the weight of shrinking multiple sclerosis and Spinraza franchises. The near term still hinges on how quickly Leqembi, Skyclarys, Qalsody, and Zurzuvae can scale, while the biggest risk remains concentrated exposure to just a few high‑stakes products. The RayThera deal and Salanersen’s Breakthrough Therapy status look helpful, but do not yet change that core risk.

Among the recent updates, the US$1.00 billion RayThera acquisition feels most relevant here, because it directly tests Biogen’s ability to use bolt‑on deals to broaden its neurology pipeline. If RayThera’s assets progress well, they could help balance the pressure from biosimilars and pricing on legacy drugs over time, alongside Salanersen and other late‑stage candidates that investors are watching closely as potential incremental growth drivers.

Yet, against this progress, investors should be aware of how quickly intensifying biosimilar competition and payer pushback could start to...

Biogen's narrative projects $10.7 billion revenue and $2.2 billion earnings by 2029.

Uncover how Biogen's forecasts yield a $219.27 fair value, in line with its current price.

Exploring Other Perspectives

Some of the lowest‑target analysts were already assuming Biogen’s revenue could slip toward US$8.6 billion with a lower future PE, so if you worry about payer pushback and tougher pricing after the RayThera news, their more cautious view might feel closer to your own than the consensus.

Explore 6 other fair value estimates on Biogen - why the stock might be worth 30% less than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Biogen research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Biogen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Biogen's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
• Outshine the giants: these 15 early-stage AI stocks could fund your retirement.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.